Merck to acquire Caraway Therapeutics in up to $610M dealnews2023-11-21T12:27:30+00:00November 21st, 2023|Endpoints News|
BeiGene licenses CDK2 inhibitor from Ensem in potential $1.33B dealnews2023-11-21T12:14:44+00:00November 21st, 2023|Endpoints News|
GSK to start PhIII trials, invest in manufacturing for sustainable inhalernews2023-11-21T11:48:02+00:00November 21st, 2023|Endpoints News|
MorphoSys’ pelabresib meets PhIII primary endpoint but misses on key secondarynews2023-11-21T11:40:21+00:00November 21st, 2023|Endpoints News|
Landmark CRISPR approval; Why don’t investors like Verve’s base editing data?; Janet Woodcock to retire; Late Friday IPO filing; and morenews2023-11-18T11:00:28+00:00November 18th, 2023|Endpoints News|
Carmot Therapeutics files for IPO as it pursues obesity and diabetes worknews2023-11-17T23:12:37+00:00November 17th, 2023|Endpoints News|
Merck cough drug fails to win adcomm’s backing as FDA raises efficacy questionsnews2023-11-17T21:10:24+00:00November 17th, 2023|Endpoints News|
Pfizer, Astellas clinch expanded approval for Xtandi in earlier line of prostate cancernews2023-11-17T20:20:09+00:00November 17th, 2023|Endpoints News|
Q&A with Judith Ng-Cashin, CRO Novotech’s chief medical officer, on 2023 and beyondnews2023-11-17T19:35:55+00:00November 17th, 2023|Endpoints News|
AbbVie advises frustrated psoriasis patients to get ‘Real Clear’ in new awareness campaignnews2023-11-17T18:23:46+00:00November 17th, 2023|Endpoints News|
